SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 — Satsuma Pharmaceuticals, Inc. (“Satsuma” or “the Company”) today announced that it will participate in two upcoming investor conferences:
- 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27 at the Lotte New York Palace in New York, NY.
- Cowen 39th Annual Health Care Conference on Monday, March 11 at the Boston Marriott Copley Place in Boston, MA.
About Satsuma Pharmaceuticals
Satsuma Pharmaceuticals is a biopharmaceutical company focused on developing STS101 as an important and differentiated therapeutic option for the acute treatment of migraine. STS101 is a novel and proprietary investigational drug-device combination product specifically designed to enable intranasal administration of the anti-migraine drug, dihydroergotamine (DHE), with a pharmacokinetic profile optimized to provide consistent and robust clinical efficacy. In developing STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, self-administered, and non-injectable DHE product. The Company believes STS101 will be an attractive migraine treatment option for many patients and may enable a larger number of migraine sufferers to realize the long-recognized therapeutic benefits of DHE therapy. STS101 has undergone extensive pre-clinical optimization and recently completed a Phase 1 clinical trial. Satsuma plans to initiate a randomized, double-blind, placebo-controlled Phase 3 clinical trial in the third quarter of 2019 to evaluate the efficacy and safety of STS101 as an acute treatment for migraine.